AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients

 
• By Alaric DeArment
  
Migraine word written on wood block
AbbVie announced positive Phase III data for Qulipta in chronic migraine • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D